Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
The University of Texas MD Anderson Cancer Center · Stem Cell Institute
Abstract
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy.
Citation impact
- FWCI
- 109.15
- Percentile
- 100%
- References
- 37
Authors
27- ELEnli LiuCorresponding
The University of Texas MD Anderson Cancer Center, Stem Cell Institute
- DMDavid Marín
The University of Texas MD Anderson Cancer Center, Stem Cell Institute
- PPPinaki P. Banerjee
The University of Texas MD Anderson Cancer Center, Stem Cell Institute
- HAHomer A. Macapinlac
The University of Texas MD Anderson Cancer Center, Stem Cell Institute
- PAPhilip A. Thompson
The University of Texas MD Anderson Cancer Center, Stem Cell Institute
Topics & keywords
- Chimeric antigen receptor
- CD19
- Natural killer T cell
- Natural killer cell
- Cancer research
- Lymphokine-activated killer cell
- Immunology
- Cell
- Good health and well-being